To gain further insight into the genetic architecture of psoriasis, we conducted a meta-analysis of 3 genome-wide association studies (GWAS) and 2 independent data sets genotyped on the Immunochip, including 10,588 cases and 22,806 controls. We identified 15 new susceptibility loci, increasing to 36 the number associated with psoriasis in European individuals. We also identified, using conditional analyses, five independent signals within previously known loci. The newly identified loci shared with other autoimmune diseases include candidate genes with roles in regulating T-cell function (such as RUNX3, TAGAP and STAT3). Notably, they included candidate genes whose products are involved in innate host defense, including interferon-mediated antiviral responses (DDX58), macrophage activation (ZC3H12C) and nuclear factor (NF)-kB signaling (CARD14 and CARM1). These results portend a better understanding of shared and distinctive genetic determinants of immune-mediated inflammatory disorders and emphasize the importance of the skin in innate and acquired host defense.
Psoriasis is a chronic, potentially disfiguring immune-mediated inflammatory disease of the skin with a prevalence of 0.2-2%, depending on the population of origin. Approximately one-quarter of individuals with psoriatics develop painful and debilitating arthritis, and there is increasing awareness of comorbidities, including metabolic syndromes and cardiovascular disease 1, 2 . Current evidence suggests that a dysregulated cutaneous immune response, characterized by tumor necrosis factor (TNF)-α dependence and exaggerated helper T cell 1 (T H 1) and 17 (T H 17) activation, occurs in genetically susceptible individuals 1, 2 . Recent large-scale association studies have identified 26 loci that are associated with psoriasis 3-10 , 21 of which show association in individuals of European ancestry [3] [4] [5] [6] 10 . Several of these loci overlap with those identified as being associated with other autoimmune diseases (for example, Crohn's disease, ankylosing spondylitis and celiac disease), particularly those near genes involved in T H 17 differentiation and interleukin (IL)-17 responsiveness (for example, IL23R, IL12B, IL23A and TRAF3IP2) 11 . To accelerate the understanding of the genetic architecture of psoriasis, we helped design a custom SNP array-the Immunochip-with the aim of fine mapping previously identified genome-wide significant susceptibility loci (associated at P < 5 × 10 −8 ) and exploring replication of thousands of SNPs representing additional promising signals 12, 13 . In this study, we used Immunochip data to identify new susceptibility loci for psoriasis and to consider their association to other autoimmune disorders.
We combined three existing GWAS data sets (referred to as Kiel 3 , the Collaborative Association Study of Psoriasis (CASP) 4 and the Wellcome Trust Case Control Consortium 2 (WTCCC2) 5 ) with two independent case-control data sets of individuals of European descent genotyped on the Immunochip: the Psoriasis Association Genetics Extension (PAGE: 3,580 cases and 5,902 controls) and the Genetic Analysis of Psoriasis Consortium (GAPC: 2,997 cases and 9,183 controls) (data sets are described in Supplementary Tables 1 and 2) . After quality control, the combined data set consisted of 10,588 individuals with psoriasis and 22,806 healthy controls. For each GWAS, we increased the SNP density through imputation, using European haplotype sequences generated by the 1000 Genomes Project (20100804 release) as templates. Overall, our analysis included 111,236 SNPs that were genotyped in both Immunochip data sets that also had good imputation quality in at least 2 of the 3 GWAS (Online Methods).
From meta-analysis of all five data sets, we confirmed associations at genome-wide significance for SNPs at 19 of the 21 known loci involved in psoriasis ( Table 1 , Supplementary Fig. 1 and Supplementary  Table 3 ). We found nominal evidence of association for the remaining two loci in the combined analysis (ZMIZ1 and PRDX5, each with P < 3 × 10 −6 ), as well as nominal evidence of association for all loci in separate analyses including only GWAS (all with P < 5 × 10 −3 ) or Immunochip data (all with P < 4 × 10 −4 ). In addition, we identified 15 new risk loci associated at P < 5 × 10 −8 ( Table 1 , Supplementary Fig. 1 and Supplementary Table 3 ). Nine of the new signals were submitted, during design of the Immunochip, as genome-wide significant Immunochip loci by at least one other disease consortium ( Supplementary Table 4 , disease overlap), although we also submitted three of these (rs11121129, rs10865331 and rs9504361) on the basis of a preliminary meta-analysis of our GWAS data sets. Notably, of the remaining six signals, four were submitted for psoriasis (rs11795343, rs4561177, rs11652075 and rs545979). The strongest new association was observed for rs892085 at 19p13.2 near the ILF3 and CARM1 genes (combined P value (P combined ) = 3.0 × 10 −17 ; odds ratio (OR) = 1.17). Despite its proximity (< 500 kb away) to TYK2, conditional analysis showed that this SNP represents an independent signal (Supplementary Table 5 ). Other associated loci included 1p36.11 near RUNX3, 6p25.3 near EXOC2 and IRF4, 9p21.1 near DDX58, 11q22.3 near ZC3H12C, 11q24.3 in the ETS1 gene and 17q21.2 near STAT3, STAT5A and STAT5B. The functional characteristics of notable genes from the newly identified loci are summarized in Box 1, and regional association plots are shown in Supplementary Figure 2 .
l e t t e r s
To identify independent secondary signals, we performed conditional analysis, using as covariates the strongest signals from the 34 loci achieving genome-wide significance in this study. We identified secondary signals in five loci: 2q24.2, 5q15, 5q33.3, 6p21. 33 and 19q13.2 (Supplementary Figs. 3 and 4 and Supplementary Tables 6  and 7) . The strongest signal from the conditional analysis mapped to the major histocompatibility (MHC) region near the MICA gene (rs13437088: P = 3.1 × 10 −40 ; OR = 1.32), in agreement with a previous conditional analysis 14 . The conditional signal at 5q15 was in the ERAP2 gene (rs2910686: P = 2.0 × 10 −8 ), which did not show any evidence of association in the unconditioned analysis (P = 0.46). Further investigation showed that the risk-increasing alleles at ERAP1 and the risk-decreasing alleles at ERAP2 preferentially appear on the same haplotype, and the signal near ERAP2 was thus masked by ERAP1 before conditional analysis (Supplementary Note).
The strongest conditional signal in the 19q13.2 region was rs12720356 in the TYK2 gene (OR = 1.25; minor allele frequency (MAF) in controls = 0.09; P = 3.2 × 10 −10 ). The association of this SNP with psoriasis has been previously reported 5 and is independent of the strongest signal in TYK2 identified by our meta-analysis (rs34536443: OR = 1.88; MAF in cases = 0.03; P = 1.5 × 10 −39 ). Because rs34536443 was a low-frequency imputed SNP and manifested the greatest effect outside of the MHC region, we directly genotyped this SNP in 3,390 independent samples from Michigan (1,844 cases and 1,546 controls), robustly replicating the association (OR = 2.80; MAF in cases = 0.02; P = 7.8 × 10 −14 ) and experimentally confirming the validity of our imputation procedures.
We next tested for statistical interaction among the top SNPs in the 34 significantly associated loci ( Supplementary Table 8 and Supplementary Note). We identified two significant pairwise interactions after For previously identified susceptibility loci, the most significantly associated SNP within 500 kb (3 Mb for the MHC region) of the previously published SNP is shown. rs34536443 was the most significantly associated SNP in the TYK2 region but was found to be independent of the previously published SNP (rs12720356). GWAS P value, P value from the meta-analysis of the three GWAS data sets; Immunochip P value, the result of the meta-analysis of the two Immunochip data sets; combined P value, the P value from the meta-analysis including all five data sets; RAF, risk allele frequency; notable genes, genes most likely to have an effect on the development of psoriasis; chr., chromosome. a The overall OR was calculated using the effective sample size.
npg l e t t e r s correction for multiple testing (P < 5 × 10 −5 ): HLA-C (rs4406273) with LCE (rs6677595) and HLA-C (rs4406273) with ERAP1 (rs27432). These interactions confirm the results of previous studies 5, 15, 16 .
To identify potential causal alleles in coding sequence, we looked for missense variants in tight linkage disequilibrium (LD; r 2 > 0.9 in 1000 Genomes Project European samples) with the lead SNP at each of the 34 identified loci ( Table 1 and Supplementary Table 6 ). We found ten potentially causal SNPs ( Table 2) , nine of which were included in our meta-analysis. For the known loci near TRAF3IP2 and TYK2, damaging nonsynonymous substitutions were themselves the index SNPs in our initial and conditional analyses.
For the newly identified loci, the index SNP from CARD14, a gene that harbors Mendelian variants predisposing to psoriasis 17 , was also a common and damaging variant, as has been described elsewhere 18 . For the remaining loci, we could account for essentially all index SNP signals by conditioning on nearby missense SNPs, consistent with the possibility that they are causal. Notable nonsynonymous variants included the protective polymorphism encoding a p.Arg381Gln alteration in IL23R 19 , a SNP in the PRSS53 gene 20 , which is also the most highly overexpressed gene in psoriatic skin in this locus 6 , and a variant in YDJC that also increases risk for celiac disease 21 , rheumatoid arthritis 22 and Crohn's disease 23 .
Box 1 Annotated functions of notable candidate genes within newly identified psoriasis susceptibility loci RERE, SLC45A1, ERRFI1 and TNFRSF9 (1p36.23): The signal falls between the RERE, SLC45A1, ERRFI1 and TNFRSF9 genes. RERE encodes an arginine-glutamic acid dipeptide repeat-containing protein that controls retinoic acid signaling 38 . ERRFI1 encodes a feedback inhibitor of the epidermal growth factor (EGF) receptor 39 . SLC45A1 encodes a solute carrier protein that mediates the uptake of glucose 40 . The TNFRSF9 gene encodes a costimulatory molecule that has a role in the generation of memory CD8 + T cells.
RUNX3 (1p36.11): RUNX3 encodes a member of the Runt domain-containing family of transcription factors and has an essential role in T-cell biology, particularly in the generation of CD8 + T cells. RUNX3 also has a role in promoting T H 1 differentiation through binding to T-bet 41 .
B3GNT2 (2p15): B3GNT2 is a member of the β-1,3-N-acetylglucosaminyltransferase family. It catalyzes the initiation and elongation of poly-N-acetyllactosamine chains 42 . Deficiency for it has been shown to result in hyperactivation of lymphocytes 43 .
EXOC2 and IRF4 (6p25.3): EXOC2 encodes a component of the multiprotein complex that mediates the docking of exocytic vesicles to the plasma membrane 44 .
IRF4 encodes a transcription factor that regulates IL17A promoter activity and controls RORyt-dependent T H 17-mediated colitis in vivo 45, 46 . IRF4 also has a role in the stabilization of the T H 17 phenotype through IL-21 (ref. 47 ) and may regulate CD4 and/or CD8 T-cell differentiation through regulation of RUNX3 expression 48 .
TAGAP (6q25.3): TAGAP encodes a RhoGTPase-activating protein that is involved in T-cell activation 49 .
ELMO1 (7p14.2-7p14.1): ELMO1 encodes a member of the engulfment and cell motility protein family, which binds to DOCK2 and is essential for Toll-like receptor (TLR7 and TLR9)-mediated interferon (IFN)-α induction by plasmacytoid dendritic cells 50 and plasmacytoid dendritic cell migration 51 . DOCK2 also has a role in antigen uptake and presentation and lymphocyte trafficking 51 . regulates the production of type I and II IFN 54 .
KLF4 (9p31.2): KLF4 encodes a Kruppel-like transcription factor, which is required for the establishment of skin barrier function 55 and regulates key signaling pathways related to macrophage activation 56 . The KLF4 protein also binds to the promoter of IL17A and positively regulates its expression. It regulates T H 17 differentiation by maintaining STAT3 transcriptional activity 62 and interacts with TYK2 in cytokine signaling 63 . MBD2, POLI and STARD6 (18q21.2): MBD2 encodes a transcriptional repressor that binds to methylated DNA and has a role in the generation of memory CD8 + T cells 68 . POLI encodes an error-prone DNA polymerase, which contributes to the hypermutation of immunoglobulin genes 69 npg l e t t e r s Using the results of a large-scale study of gene expression in psoriatic versus normal skin 24 , we found 14 upregulated genes (IL12RB2, LCE3D, REL, PUS10, CDSN, PRSS53, PRSS8, NOS2, DDX58, ZC3H12C, SOCS1, STAT3, CARD14 and IFIH1) and 4 downregulated genes (MICA, RNF114, PTRF and POLI) in the 34 associated regions (false discovery rate (FDR) of <0.05; fold change of >1.5 or <0.67; Supplementary Table 9 ). The number of differentially expressed genes in psoriasis susceptibility loci was not greater than expected by chance (P = 0.39). None of the 34 top SNPs met the Bonferronicorrected significance threshold (P < 1 × 10 −7 ) for expression quantitative trait loci (eQTLs) in skin tissue, as assessed by microarray analysis of mRNA levels 25 . However, rs2910686, one of the five SNPs identified by conditional analysis, was a cis eQTL for ERAP2 in both normal and psoriatic skin (Supplementary Note). Genetic control of ERAP2 expression has been noted previously 26, 27 and has been suggested as a determinant of balancing selection at this locus 28 .
This study increases the number of psoriasis-associated regions in individuals of European ancestry to 36, with conditional analysis increasing the number of independent signals to 41. The 39 independent signals associated at P < 5 × 10 −8 in the current study collectively account for 14.3% of the total variance in psoriasis risk or approximately 22% of its estimated heritability 29 (Supplementary Table 10) , indicating that further genetic studies, including fine-mapping studies and searches for uncommon susceptibility variants, are in order.
Sharing of susceptibility loci between autoimmune diseases has been demonstrated previously 11 , and we found similar patterns of overlap in this study. Notably, ten of the psoriasis susceptibility loci reported here overlapped with those reported in Crohn's disease and ten others associated with celiac disease, diseases that occur at higher frequencies in individuals with psoriasis 30, 31 (Supplementary Fig. 5 and Supplementary Table 4 ). We caution that the statistical significance of these overlapping loci is hard to assess given the ongoing process of gene discovery for many autoimmune disorders and biases in the list of SNPs evaluated for association in this experiment.
As the primary interface with the external environment, the skin provides a critical first line of host defense to microbial pathogens. Consistent with this function, it possesses a diverse and wellconserved set of innate immune mechanisms 32, 33 that emerged long before the development of adaptive immunity 34 . In this context, we found it noteworthy that five of the six newly identified loci that are thus far uniquely associated with psoriasis are involved in innate immune responses (DDX58, KLF4, ZC3H12C, CARD14 and CARM1; Box 1 and Supplementary Table 4 ). Among all confirmed psoriasis susceptibility loci, 11 out of 14 psoriasis-specific loci (the 5 new loci involved in the innate immune response along with IL28RA, LCE3D, NOS2, FBXL19, NFKBIA and RNF114) encode plausible regulators of innate host defense 1, 2, 35 . Conversely, only 6 out of 20 loci shared with other autoimmune diseases contain genes that contribute to innate immunity (REL, IFIH1, TNIP1, TNFAIP3, IRF4 and ELMO1) . These provisional comparisons further illustrate the insights that can be gained by developing and comparing complete and well-annotated sets of risk loci for autoimmune disorders.
The known and newly identified psoriasis susceptibility loci implicated by this study encode several proteins engaged in the TNF, IL-23 and IL-17 signaling pathways, which are targeted by highly effective biological therapies 36 . Notably, our strongest non-MHC signal directly implicates TYK2, a druggable target that contributes to several autoimmune diseases. Agents targeting the closely related JAK kinases are showing encouraging results in clinical trials 37 . Our findings will help prioritize and interpret the results of sequencing and gene expression studies. Further genomic studies are needed to identify the underlying causal variants in these psoriasis susceptibility loci and to bring increased understanding of pathogenetic mechanisms. 
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The samples from GAPC substantially overlapped with those described as replication data sets in Strange et al. 5 . All cases had been diagnosed as having psoriasis vulgaris. The GAPC cases and the Irish and Spanish controls were genotyped at the Wellcome Trust Sanger Institute, and all samples were provided by the relevant groups listed in Supplementary Table 2 and by the members of the GAP Consortium listed in the Supplementary Note. The UK controls were the WTCCC common control samples that did not overlap with the samples included in the original GWAS (the data set consisted of 6,740 1958 British Birth cohort and 2,900 UK Blood Service samples genotyped at the Wellcome Trust Sanger Institute and the University of Virginia). The German controls were obtained from the PopGen Biobank and genotyped at the Institute of Clinical Molecular Biology at Christian-Albrechts-University of Kiel. The Finland control data were from the DILGOM collection 70 . The Irish controls were provided by the Irish Blood Transfusion Service/Trinity College Dublin Biobank, and Irish cases were collected with the aid of the Dublin Centre for Clinical Research. We did not include specific controls from Austria or Sweden, but principal-components analysis suggested that the cases from these cohorts were well matched to the controls from The Netherlands and Germany.
For the PAGE Immunochip study, samples also substantially overlapped with previously published replication data sets. The German cases (described as a replication data set in Ellinghaus et al. 3 ) and all samples from the United States and Canada, as well as 439 Estonian cases from the University of Tartu, were genotyped at the Institute of Clinical Molecular Biology at Christian-Albrechts-University of Kiel. The respective samples were provided by the groups listed in Supplementary Table 2 and by the members of PAGE listed in the Supplementary Note. The German controls were obtained from a population-based sample from the general population living in the region of Augsburg in southern Germany (KORA S4/F4) 71 , which was genotyped at the Helmholtz Zentrum Munich, and from the population-based epidemiological HNR study, for which genotyping was performed at the Life and Brain Center at the University Clinic in Bonn. The remaining Estonian samples were obtained from and genotyped at the Estonian Genome Center University of Tartu (EGCUT).
Genotyping panel and SNPs. The Immunochip is a custom Illumina Infinium high-density array consisting of 196,524 variants (after Illumina quality control) compiled largely from variants identified in previous GWAS of 12 different immune-mediated inflammatory diseases, including psoriasis 13 . The main aims of the Immunochip were deeper replication and fine mapping of genome-wide significant loci, as well as increasing power to promote promising but less significant SNPs to genome-wide significance. For fine mapping, SNPs within 0.2 cM on either side of the GWAS top SNPs at 186 loci were selected from 1000 Genomes Project 72 low-coverage pilot Utah residents of Northern and Western European ancestry (CEU) sequencing data as well as additional variants identified by resequencing from groups involved in the chip design. For promotion of promising signals and those not quite reaching genome-wide significance, each disease-focused group was allowed to submit approximately 3,000 additional SNPs. We submitted 17 of the 19 confirmed regions associated with psoriasis at genome-wide significance ( Table 1) for fine mapping on the basis of a preliminary meta-analysis of our data, and 1 of the confirmed signals (IL28RA) and 9 of the new psoriasis-associated signals ( Supplementary Table 5 , disease overlap) were submitted for finemapping by groups studying other diseases (although we also submitted 3 of these as part of our additional SNP allocation: rs11121129, rs10865331 and rs9504361). Six additional signals were detected on the basis of additional SNP allocation in individual groups; four of these (rs11795343, rs4561177, rs11652075 and rs545979) were submitted by our group. All Immunochip samples were genotyped as described in Illumina's protocols.
Genotype calling. For the PAGE data set, genotype calling was performed using Illumina's GenomeStudio Data Analysis software and the customgenerated cluster file of Trynka et al. 13 . (which was generated by initial clustering of 2,000 UK samples with the GenTrain2.0 algorithm and subsequent manual readjustment and quality control). Genotype calling for the GAPC data set was performed using GenoSNP 73 from allele intensities, except for the German, Italian, Dutch and Finnish controls, which were called using the same method described for the PAGE data set.
Imputation.
To increase the number of overlapping SNPs between data sets, we performed imputation on the 3 GWAS data sets using minimac 74 (Kiel and CASP) and IMPUTE2 (refs. 75,76) (WTCCC2) using data from CEU reference haplotypes from the 1000 Genomes Project 72 (December 2010 version of the 10/08/04 sequence and alignment release containing 629 individuals of European descent). SNPs with low imputation quality (r 2 ≤ 0.3 for minimac and info score < 0.5 for IMPUTE2) were removed. For all 3 data sets, cases and controls were imputed together.
Sample and genotype quality control. For the Immunochip data sets, we first excluded SNPs with a call rate below 95% or with a Hardy-Weinberg equilibrium P value of <1 × 10 −6 . Samples with less than SNP call rates below 98% were then excluded. Because the Immunochip includes a large proportion of fine-mapping SNPs that are associated with autoimmune disease, we used a set of independent SNPs that have P values >0.5 from the meta-analysis of the three GWAS data sets as a quality control tool for each individual Immunochip data set. Using the HapMap 3 samples as reference 77 , we performed principal-component analysis to identify and remove samples with non-European ancestry. We also removed samples with extreme inbreeding coefficients or heterozygosity values computed by PLINK 78 .
To assess possible stratification in the data sets, principal-components analysis was also performed in each of the Immunochip data sets separately (excluding HapMap). There was no evidence of stratification between the cases and controls of each sample group. However, as expected, the top principal components did separate the samples well by country of origin. The use of the top ten eigenvectors as covariates in the analysis did not completely correct for stratification, and, therefore, a linear mixed-model method (efficient mixed-model association expedited (EMMAX)) was instead used for the association analysis. These methods have been shown to outperform principal components in correcting for this type of population stratification and cryptic relatedness 79 , which is becoming more common as sample sizes increase and studies comprise more collaborative efforts.
To identify duplicate pairs or highly related individuals among data sets, we used a panel of 873 independent SNPs that were genotyped in both the GWAS and Immunochip samples and performed pairwise comparisons using the genome function in PLINK 78 , requiring Pi-HAT of ≥0.5. We identified 1,142 (885 from GAPC and 257 from PAGE) related sample pairs (mostly duplicates) and removed one sample from each pair. We also removed 4,828 controls from the UK common Immunochip controls because of duplication in the WTCCC2 GWAS sample. For GWAS samples that were duplicated in the Immunochip data sets (the majority of duplicates), we removed the samples from the Immunochip data sets to keep the previously published data sets intact.
The GWAS data sets underwent quality control as previously described and were analyzed for association using the top principal components from the previous analyses as covariates [3] [4] [5] .
We visually inspected the signal intensity cluster plots for all SNPs with associations reaching genome-wide significance to confirm high-quality genotype calling.
Genomic control. Genomic control inflation factors for the five data sets were 1.09. (Kiel), 1.06 (CASP), 1.04 (WTCCC2), 0.99 (PAGE) and 0.96 (GAPC), indicating that population structure and cryptic relatedness were adequately controlled for in these data sets. Because the Immunochip was designed for deep replication and fine mapping of loci associated with autoimmune npg
